Navigation Links
Global Market for Minimally Invasive Vertebral Compression Fracture Treatments Will Reach $925 Million by 2022
Date:9/3/2014

BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that the global market for minimally invasive vertebral compression fracture (MIVCF) treatments will reach a value of $925 million by 2022, driven by an increasing prevalence of osteoporosis, which is largely the result of an aging population. In addition, marketing activity and positive clinical data will spur increasing use of these devices in the tumor and trauma indications, supporting overall procedure volumes.

Other key findings from Decision Resources Group's coverage of the global MIVCF treatment market:

  • Global price declines: Price competition and economic challenges will negatively impact average device prices. Financial concerns will be particularly evident in European countries such as Italy, where the effects of the eurozone crisis are still lingering.
  • Rapidly expanding revenues in Japan: The Japanese market will see the strongest revenue growth, driven by the recent reimbursement approval and subsequent rapid adoption of Medtronic's Kyphoplasty product in the vertebral augmentation segment.
  • Steady U.S. forecast: Despite issues with reimbursement that hindered procedure volume growth in 2013, the United States market will remain the largest but lowest growth market through 2022; currently this market represents approximately two-thirds of total global revenues.

Comments from Decision Resources Group Senior Analyst Brady Baker:

  • "Medtronic holds the majority of revenues in the global MIVCF treatment market, largely as a result of its stronghold in the vertebral augmentation space. Additional competitors will look to capture market share, however, by launching innovative and lower-cost products. For example, both CareFusion and DFINE have gained strong market shares by incorporating unique features and low price points into their product portfolios."

Comments from Decision Resources Group Analyst Valentina Lim:

  • "Poor or nonexistent reimbursement will limit overall revenue expansion in some markets. For example, unfavorable reimbursement for vertebroplasty—particularly in Australia and Japan—will somewhat limit growth in the Asia Pacific region."

Additional Resources:

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort  
781-993-2597  
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Bone Cement and Accessories Market Is Set to Expand from $630 Million in 2013 to Over $1 Billion by 2022
2. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
3. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
4. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
5. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
6. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
7. Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
8. Global Markets and Technologies for Molecular Imaging Devices
9. Bariatric Surgery: Global Markets for Services and Devices
10. Acute Heart Failure Global Clinical Trials Review, H2, 2014
11. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):